Drug Trial Radar · NCT04830215
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Apr 1, 2021
Primary completion
May 27, 2022
Study completion May 27, 2022
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- Collaborators
- Lundbeck Canada Inc.; Otsuka Canada Pharmaceutical Inc.
- First posted
- Apr 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.
Conditions
- Major Depressive Disorder
Interventions
BrexpiprazoleDrug
Oral brexpiprazole tablets as adjunctive therapy to ADT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in IDS-SR-10 EngagementTime frame: Baseline to Week 8
- Change From Baseline in IDS-SR Total ScoreTime frame: Baseline to Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chatham-Kent Clinical Trials Research Centre
Chatham, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.